Liquid biopsy is one of the promising non-invasive method for the diagnosis of cancer. It involves the sampling of tissue in the liquid state. It is a simple and painless method for cancer diagnostic as compared to other diagnostics methods.
Global Liquid Biopsy Market Information, by Biomarker Types (Circulating Tumor Cells (Ctcs), Circulating Tumor Dna (Ctdna), Extracellular Vesicles (Evs) and Other Biomarker (Circulating Rna And Proteins), by Application (Cancer Therapeutic Application, Reproductive Health, Other Therapeutic Application), by Sample (Blood Sample, Urine Sample, Other) And End User (Hospitals and Laboratories, Academic And Research Centers, Other End Users) – Forecast to 2022.
Therefore, liquid as well as solid biopsy are important for cancer management, and creates excellent growth opportunities in the market. The technology is further applicable for monitoring cardiac and neurologic disease, early detection and evaluation of drug resistance, and prenatal testing. It can now be applied to organ transplant monitoring to bridge the gap between need of new technology, and rising demand.
Exclusive Sample Copy @ https://www.marketresearchfuture.com/sample_request/710 .
Driver & Restrains:
Increasing awareness about personalized cancer care is ruling the global liquid biopsy market. The market is driven by increasing demand for non-invasive testing, increasing prevalence of cancer, and extensive research and development in the cancer diagnosis and treatment. The market is also driven by number of advantages of liquid biopsies such as quick analysis, identification of specific mutations, low cost, and r less labor required. Furthermore, rising awareness about the diagnosis of various types of cancer stimulate the market growth. However, tumor heterogeneity, remaining the biggest challenge in cancer research, may restrain the growth of the market.
Strategic Approaches by Key Players:
Guardant Health, Inc., Trovagene, Inc., Agena Bioscience Inc. Inc., Admera Health, Biocept, Inc., Circulogene Theranostics, Inivata Ltd., SAGA Diagnostics AB, Exosome Diagnostics, and Bio-Rad Laboratories, Inc., Agena Bioscience Inc. Inc. are major players in the liquids biopsy market. The key players in the market are focusing on the development of new diagnostics methods and tools, as well as various strategic approaches such as acquisitions, partnership, and collaboration. Fund raising for cancer research is one to the important tasks for the key players to development new diagnostics devices and technologies as well as hold their position in the market.
In January 2017, Guardant Health Inc. and MD Anderson and announce partnership to make comprehensive liquid biopsy part of oncology standard of care.
In September, 2016, Guardant Health Inc. expanded the distribution of Guardant360, a genomic cancer test, to gain grounds in the Middle East
In June, 2016, Guardant Health Inc. and Oncotest-Teva entered into a distribution and marketing partnership for Guardant360 in Israel
Bio-Rad Laboratories, Inc.:
In January, 2017, Bio-Rad Laboratories, Inc. acquired RainDance Technologies outreach next generation sequencing applications and strengthen their position in the area of Droplet Digital PCR.
These developments help to determine the growth of the market across the globe, which is significantly lighted by partnerships and geographical expansion.
Order a Premium 90 Pages Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=710 .
Cancer Research and Liquid Biopsy:
In February 2016, Circulogene Theranostics entered into a research agreement with the University of Alabama Birmingham (UAB) Comprehensive Cancer Center.
In December 2015, for example, researchers at the San Antonio Breast Cancer Symposium reported the use of cfDNA liquid biopsies to evaluate the prognosis after treatment in breast cancer patients enrolled in two phase III clinical trials.
Additionally, researcher have now successfully applied liquid biopsy to determine the prognosis of patients with colon cancer in phase II. Therefore, increasing applications of liquid biopsy in cancer research is another important driver for the growth of the market.
Major Table of Content for Liquid Biopsy Market:
1 Report Prologue
2.1 Scope of Study
2.2 Research Objective
2.3 Assumptions & Limitations
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
Ask to expertise @ https://www.marketresearchfuture.com/sample_request/710 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312